3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
31
Carcinoma, Hepatocellular
18
Neoplasms
13
Neoplasm Metastasis
13
Melanoma
13
Esophageal Neoplasms
12
Nasopharyngeal Carcinoma
10
Head and Neck Neoplasms
9
Esophageal Squamous Cell Carcinoma
9
Colorectal Neoplasms
9
Squamous Cell Carcinoma of Head and Neck
8
Breast Neoplasms
8
Triple Negative Breast Neoplasms
7
Stomach Neoplasms
7
Recurrence
7
Pancreatic Neoplasms
7
Rectal Neoplasms
6
Carcinoma, Renal Cell
6
Biliary Tract Neoplasms
6
Lung Neoplasms
5
Small Cell Lung Carcinoma
4
Sarcoma
4
Ovarian Neoplasms
4
Locally Advanced Rectal Cancer
4
Colonic Neoplasms
4
Advanced NSCLC
4
Urinary Bladder Neoplasms
3
Prostatic Neoplasms
3
Liver Neoplasms
3
Leukemia, Myeloid, Acute
3
Interventions
Paclitaxel
95
Carboplatin
77
pembrolizumab
74
Cisplatin
29
Bevacizumab
27
Letrozole
22
Radiotherapy
21
Doxorubicin
21
Megestrol Acetate
20
lenvatinib
19
olaparib
18
Taxes
17
Docetaxel
17
Nivolumab
16
Specimen Handling
15
Metformin
15
dostarlimab
14
Magnetic Resonance Spectroscopy
14
Gemcitabine
13
durvalumab
12
Medroxyprogesterone Acetate
12
Trastuzumab
11
Indocyanine Green
11
Fulvestrant
11
Biopsy
11
temsirolimus
10
abemaciclib
10
atezolizumab
9
Radiation
9
Early Intervention, Educational
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Endometrial Neoplasms
×
Immune Checkpoint Inhibitors
×
Clear all
NCT06710847
2026-02-02
SYLVER
GlaxoSmithKline
Phase 1/2
Active not recruiting
14 enrolled